Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: Results from the ASSET trial

被引:59
|
作者
Goldstein, J
Silberstein, SD
Saper, JR
Elkind, AH
Smith, TR
Gallagher, RM
Battikha, JP
Hoffman, H
Baggish, J
机构
[1] San Francisco Clin Res Ctr, San Francisco Headache Clin, San Francisco, CA 94109 USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Michigan Head Pain & Neurol Inst, Ann Arbor, MI USA
[4] Elkind Headache Ctr, Mt Vernon, NY USA
[5] Ryan Headache Ctr, Chesterfield, MO USA
[6] UMDNJ, Sch Osteopath Med, Moorestown, NJ USA
[7] Bristol Myers Squibb Co, Plainsboro, NJ USA
来源
HEADACHE | 2005年 / 45卷 / 08期
关键词
migraine; early treatment; clinical trial; sumatriptan; nonprescription medication; caffeine;
D O I
10.1111/j.1526-4610.2005.05177.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective. - To address the need for a rigorous, direct comparison of prescription and over- the-counter ( OTC) migraine drugs and to expand the database on early treatment of migraine. Background. - Most people who experience migraine use OTC medications to treat their symptoms, but no head-to-head clinical trials comparing these agents with prescription migraine therapies have been published. In addition, even though most migraineurs treat early in the attack, few studies have been conducted to reflect this treatment pattern. Methods. - We compared a combination of nonprescription migraine medication ( acetaminophen 500 mg, aspirin 500 mg, and caffeine 130 mg) with a prescription migraine product ( 50 mg sumatriptan) in a randomized, controlled clinical trial in which subjects treated at the first sign of a migraine attack. Subjectswho reported vomiting during more than 20% of migraine episodes or who required bedrest during more than 50% of migraine episodes were excluded from the study. Of the 188 subjects randomized, 171 took study medication and were included in the analysis. Conclusion. - The combination of acetaminophen, aspirin, and caffeine was significantly more effective ( P > .05) than sumatriptan in the early treatment of migraine, as shown by superiority in summed pain intensity difference, pain relief, pain intensity difference, response, sustained response, relief of associated symptoms, use of rescue medication, disability relief, and global assessments of effectiveness. An additional, larger clinical trial is needed to confirm these results.
引用
收藏
页码:973 / 982
页数:10
相关论文
共 50 条
  • [21] EFFICACY OF SUBCUTANEOUS SUMATRIPTAN IN THE ACUTE TREATMENT OF EARLY-MORNING MIGRAINE - A PLACEBO-CONTROLLED TRIAL
    BOUSSER, MG
    DALLENS, H
    RICHARD, A
    BES, A
    COQUILLAT, G
    CHATEL, M
    CHAZOT, G
    HENRY, P
    LARMANDE, P
    MIHOUT, B
    PETIT, H
    PRADALIER, A
    RASCOL, A
    TOURNILHAC, M
    VERRET, JM
    JOURNAL OF INTERNAL MEDICINE, 1993, 234 (02) : 211 - 216
  • [22] Cost-effectiveness of eletriptan versus sumatriptan: Results from a randomized, controlled trial
    Weis, K
    Perfetto, E
    Mullins, CD
    Healey, P
    Subedi, P
    Meng, F
    VALUE IN HEALTH, 2006, 9 (03) : A83 - A83
  • [23] Early Onset of Efficacy With Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
    Ailani, Jessica
    Reuter, Uwe
    Graboski, Corrie
    Klein, Brad C.
    Yu, Sung Y.
    Nagy, Krisztian
    Guo, Hua
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 32 - 33
  • [24] Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta-analysis of randomized placebo-controlled trials
    Diener, Hans Christoph
    Gaul, Charly
    Lehmacher, Walter
    Weiser, Thomas
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (01) : 350 - 357
  • [25] Predictors of treatment-response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti-inflammatory drugs in acute treatment of episodic migraine
    Ezzati, Ali
    Fanning, Kristina M.
    Reed, Michael L.
    Lipton, Richard B.
    HEADACHE, 2023, 63 (03): : 342 - 352
  • [26] Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial
    Joharatnam-Hogan, Nalinie
    Cafferty, Fay
    Hubner, Richard
    Swinson, Daniel
    Sothi, Sharmila
    Gupta, Kamalnayan
    Falk, Stephen
    Patel, Kinnari
    Warner, Nicola
    Kunene, Victoria
    Rowley, Sam
    Khabra, Komel
    Underwood, Tim
    Jankowski, Janusz
    Bridgewater, John
    Crossley, Anne
    Henson, Verity
    Berkman, Lindy
    Gilbert, Duncan
    Kynaston, Howard
    Ring, Alistair
    Cameron, David
    Din, Farhat
    Graham, Janet
    Iveson, Timothy
    Adams, Richard
    Thomas, Anne
    Wilson, Richard
    Pramesh, C. S.
    Langley, Ruth
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (11): : 854 - 862
  • [27] Treatment Outcomes for Oral, Subcutaneous and Intranasal Forms of Sumatriptan: Survey Results From Migraine in America Symptoms and Treatment (MAST) Study
    Singh, P.
    Munjal, S.
    Lipton, R. B.
    Reed, M. L.
    Fanning, K. M.
    HEADACHE, 2020, 60 : 126 - 126
  • [28] Total Migraine Freedom for Breath Powered Intranasal Delivery of 22 Mg Sumatriptan Powder (AVP-825) versus 100 Mg Oral Sumatriptan from the COMPASS Study of Acute Treatment of Migraine
    Halker, R.
    Tepper, S. J.
    Siegert, S.
    Wallick, C.
    HEADACHE, 2015, 55 : 136 - 136
  • [29] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, P.
    Nagy, K.
    Tassorelli, C.
    Lanteri-Minet, M.
    Sacco, S.
    Nezadal, T.
    Finnegan, M.
    Guo, H.
    Ferreira, De Abreu R.
    Trugman, J.
    HEADACHE, 2023, 63 : 117 - 117
  • [30] TOTAL MIGRAINE FREEDOM FOR BREATH POWERED INTRANASAL DELIVERY OF 22 MG SUMATRIPTAN POWDER (AVP-825) VERSUS 100 MG ORAL SUMATRIPTAN FROM THE COMPASS STUDY OF ACUTE TREATMENT OF MIGRAINE
    Halker, R.
    Tepper, S.
    Siegert, S.
    Wallick, C.
    VALUE IN HEALTH, 2015, 18 (03) : A278 - A278